The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InTenaya Therapeutics and Alnylam Pharmaceuticals have announced a strategic research collaboration aimed at discovering novel genetic targets for cardiovascular diseases. Under the agreement, Tenaya will receive up to $10 million in upfront payments, along with research funding and potential milestone payments totaling $1.13 billion. The partnership leverages Tenaya's specialized expertise in heart disease target validation and Alnylam's industry-leading RNAi therapeutic platform. This collaboration focuses on developing disease-modifying treatments to address the underlying causes of various heart conditions. For Tenaya, the deal provides a significant capital infusion and long-term financial upside relative to its current market valuation. Meanwhile, Alnylam expands its therapeutic reach into the high-impact cardiovascular sector through this joint effort.